Non-confidential intake
We align on asset class, mechanism, indication, stage, target geographies, and current site assumptions without requiring confidential data.
Service 01
FIH Site & PI Matching
For oncology sponsors preparing a first-in-human trial, we help leadership understand which sites and investigators deserve priority diligence before the site list, CRO plan, and operating budget become hard to change.
Service detail
Problem addressed
FIH execution risk rarely lives in the average. It lives in specific sites, specific investigators, and specific mechanism contexts. A famous center may not activate quickly, and a publication-heavy PI may already be overloaded by similar studies. We organize those signals into a decision view that can surface timeline risk earlier.
What we analyze
- Public trial history matched to the asset mechanism, indication, and draft design
- Site activation experience, early oncology trial exposure, and regional execution patterns
- PI workload, adjacent trial involvement, historical behavior, and overload risk
- Patient competition and site overlap from peer assets in target regions
- Country mix, single-region concentration, and global representativeness considerations
- Questions sponsors should validate with CROs, sites, advisors, or local experts
What clients receive
- Prioritized candidate site and PI list
- Site mix recommendation and regional pathway rationale
- Activation risk, enrollment competition, and PI workload memo
- Leadership-ready deck or concise decision memo
- Next diligence questions for CRO, site, or advisor discussions
How the work moves forward
Ready to review your first-wave site assumptions?
Start with non-confidential background on mechanism, indication, target geographies, and current planning assumptions. We will assess whether a deeper review is appropriate.
Execution signal build
We analyze matched trials, site behavior, PI workload, competitive density, and country pathways to form a candidate view.
Leadership review
We walk through priorities, risk drivers, and next diligence questions so the analysis turns into operational decisions.